All In Biotech

Drug Trial Radar · NCT04211337

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 291 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

291

Actual

Start

Feb 11, 2020

Primary completion

May 22, 2023

Study completion Nov 2027

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Dec 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Conditions

  • Medullary Thyroid Cancer

Interventions

  • SelpercatinibDrug

    Administered orally

  • CabozantinibDrug

    Administered orally

  • VandetanibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)Time frame: Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months

Locations

143 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope National Medical Center

    Duarte, California

  • UCLA Hematology/Oncology - Westwood (Building 100)

    Los Angeles, California

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Emory University

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin Hospitals and Clinics

    Madison, Wisconsin

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, Australia

  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Instituto Nacional de Câncer - INCA

    Rio de Janeiro, Brazil

  • Grupo Oncoclínicas Botafogo

    Rio de Janeiro, Brazil

  • Grupo COI - Clínicas Oncológicas Integradas

    Rio de Janeiro, Brazil

  • Icesp - Instituto Do Câncer Do Estado de São Paulo

    São Paulo, Brazil

  • Centro Paulista de Oncologia Clínica

    São Paulo, Brazil

  • Oncocentro

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Cancer de Londrina

    Londrina, Paraná, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Centro de Pesquisa Sao Lucas

    Campinas, São Paulo, Brazil

  • Hospital de Clínicas de Ribeirão Preto

    Ribeirão Preto, São Paulo, Brazil

  • Hospital Sírio Libanês

    São Paulo, São Paulo, Brazil

  • Instituto D'Or de Pesquisa e Ensino (IDOR)

    São Paulo, São Paulo, Brazil

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Beijing Tongren Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital Of Fujian Medical University

    Fuzhou, Fujian, China

  • Gansu Cancer Hospital

    Lanzhou, Gansu, China

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.